As Amgen's Prolia Goes, So Goes The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Wall Street analysts' reactions are mixed as to the meaning of an FDA advisory committee's mixed votes on Amgen's denosumab.
You may also be interested in...
Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start
The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.
GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care
Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care
Amgen, GSK To Team Up On Denosumab Commercialization in Europe
Amgen's big bet on denosumab gets a boost from a Big Pharma partner in Europe, with U.S. rights intact.